Quantcast

Latest dermatitis Stories

2011-11-09 12:00:00

Steroid-free treatment for mild, moderate, and severe atopic dermatitis in adults and children South Plainfield, N.J. (PRWEB) November 09, 2011 PuraCapâ“ž¢ Pharmaceutical LLC (http://www.PuraCap.com), an emerging, fully-integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers, announces the acquisition of their first prescription brand, EpiCeram® Skin...

2011-08-18 03:00:00

LUXEMBOURG, August 18, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announced today the expansion of its senior management team with the appointment of three experienced international pharma executives. Alex Leech joins as Vice President, Head of Finance and Operations, James Sandy as Senior Vice President, Head of Development, and Peter Spargo as Senior Vice President for...

2011-07-26 06:00:00

MINNEAPOLIS, July 26, 2011 /PRNewswire/ -- Nearly every parent has experienced this distressing situation: the baby who wakes, irritable and uncomfortable, drenched in perspiration. Unfortunately, the resulting moisture then causes babies' sensitive skin to become irritated and itchy. For those parents whose children have eczema or severely sensitive skin, an overheated baby can lead to a cycle of itching and scratching which only exacerbates the sensitivity of their child's skin. To view...

2011-05-31 06:44:00

LOS ANGELES and HONG KONG, May 31, 2011 /PRNewswire-Asia/ -- Artificial Life, Inc., (OTC BB: ALIFE), a leading provider of award-winning mobile technology and applications, announced today their upcoming product Opus-M(TM) Health: Dermatitis (short form: Opus-M Health: Dt), a healthcare app specifically geared towards the monitoring of the dermatitis skin condition. Dermatitis is any condition characterized by inflammation of the skin and affects both males and females equally. In the...

2011-05-02 20:36:50

Atopic dermatitis is a form of eczema that is caused by an inappropriate inflammatory response in the skin. Many children with atopic dermatitis also have food allergies, and skin contact with food allergens can make their atopic dermatitis worse. It is unclear why this occurs, but it has been suggested that immune cells known as T cells that are sensitized by exposure to food allergens in the gut are responsible. Raif Geha and colleagues, at Harvard Medical School, Boston, have now generated...

2011-04-11 10:10:00

Nine scientists receive funds to study psoriatic disease PORTLAND, Ore., April 11, 2011 /PRNewswire-USNewswire/ -- The National Psoriasis Foundation awarded $750,000 in nine research grants to the nation's leading scientists studying psoriasis--a chronic disease of the immune system that appears on the skin, affecting as many as 7.5 million Americans--for projects with the highest likelihood of resulting in better treatments and a cure for this disease. "The National Psoriasis...

2011-03-10 02:59:00

LUXEMBOURG, March 10, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal characteristics for topical application (high...

2011-02-16 10:51:00

SAN FRANCISCO, Feb. 16, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Oculus Innovative Sciences, Inc., (Nasdaq: OCLS) and maintains its $3.81 target price. Ross Silver, Principal Analyst at Vista Partners stated, "Oculus is growing significantly as evidenced by their revenue growth of approximately 40% in each of the past two years. In addition, management has provided revenue guidance of $45-$60M in fiscal year 2013, a six fold increase from revenues...

2011-02-09 03:59:00

OXFORD, England, February 9, 2011 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales. PAP-1 is one of the most...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related